Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERNESTO BUSTINZA LINARES

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1598966509
CMS profile
299684
Location
DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,778.19

176 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,507.20 172
Long term medical supply or device loan $249.99 3
Education $21.00 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERNESTO BUSTINZA LINARES

NPI 1598966509 · CMS profile ID 299684

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

DELAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598966509?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERNESTO BUSTINZA LINARES, NPI 1598966509, CMS profile ID 299684. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598966509?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ERNESTO BUSTINZA LINARES, NPI 1598966509, CMS profile ID 299684. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598966509?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ERNESTO BUSTINZA LINARES, NPI 1598966509, CMS profile ID 299684, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 176 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1598966509?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

176 matching records · $3,778.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 176 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 176.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $29.6208/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260775 CMS
GENZYME CORPORATION $19.2908/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050081545 CMS
MorphoSys, US Inc. $17.8908/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060327203 CMS
Amgen Inc. $34.0408/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019906431 CMS
Pharmacyclics LLC, An AbbVie Company $27.8808/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998282817 CMS
Celgene Corporation $2.1008/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260797 CMS
MorphoSys, US Inc. $20.5108/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060327201 CMS
Novartis Pharmaceuticals Corporation $15.7008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806163 CMS
AbbVie Inc. $22.5508/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996339607 CMS
Exelixis Inc. $16.6708/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044587575 CMS
Genentech USA, Inc. $23.4708/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040360605 CMS
Novartis Pharmaceuticals Corporation $15.6208/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806167 CMS
Daiichi Sankyo Inc. $11.4908/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006462151 CMS
Genentech USA, Inc. $14.0808/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040360617 CMS
Kite Pharma, Inc. $28.7407/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025267705 CMS
Regeneron Healthcare Solutions, Inc. $16.8707/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999109779 CMS
GENZYME CORPORATION $16.6107/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050081537 CMS
Daiichi Sankyo Inc. $21.5207/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006424507 CMS
AstraZeneca Pharmaceuticals LP $24.0507/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015040753 CMS
Novartis Pharmaceuticals Corporation $1.8207/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806155 CMS
Novartis Pharmaceuticals Corporation $16.4607/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806159 CMS
Astellas Pharma US Inc $14.4707/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034291843 CMS
Novartis Pharmaceuticals Corporation $11.0607/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806151 CMS
Lilly USA, LLC $15.9107/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031414163 CMS
E.R. Squibb & Sons, L.L.C. $12.8107/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260695 CMS
Pharmacyclics LLC, An AbbVie Company $23.8107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998282815 CMS
Amgen Inc. $11.4107/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020576185 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $13.6607/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993435603 CMS
Pharmacyclics LLC, An AbbVie Company $28.0607/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998282813 CMS
Pharmacosmos Therapeutics Inc. $16.1106/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046243585 CMS
Amgen Inc. $15.9606/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019906435 CMS
Pharmacyclics LLC, An AbbVie Company $29.1906/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998282811 CMS
Novartis Pharmaceuticals Corporation $18.1206/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806147 CMS
Puma Biotechnology, Inc. $12.8406/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059058013 CMS
Genmab U.S., Inc. $28.9606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051344335 CMS
Amgen Inc. $18.4206/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019906427 CMS
Gilead Sciences, Inc. $27.2706/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025589239 CMS
Celgene Corporation $110.3106/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260679 CMS
Seagen Inc. $19.9606/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995667147 CMS
Novartis Pharmaceuticals Corporation $24.4306/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991806135 CMS
Amgen Inc. $15.0206/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020576183 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $83.3305/31/2023 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993435611 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $21.3405/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993435601 CMS
Amgen Inc. $10.1705/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020576181 CMS
Celgene Corporation $11.7505/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260633 CMS
CTI BioPharma Corp. $17.2405/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039689975 CMS
AstraZeneca Pharmaceuticals LP $23.2505/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015964053 CMS
Merck Sharp & Dohme LLC $18.2905/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048817971 CMS
Celgene Corporation $17.8205/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260609 CMS
Celgene Corporation $16.7405/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015260617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,481.93 178
PY2020 $1,857.32 97
PY2021 $2,588.64 93
PY2022 $2,697.42 131
PY2023 $3,778.19 176
PY2024 $2,879.25 135
PY2025 $2,919.37 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $143,827.34 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

10 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eli Lilly and Company $9,700.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187880079
Principal investigator 1 Genentech, Inc. $32,612.00 12/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211650025
Principal investigator 1 Genentech, Inc. $2,800.00 12/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211650000
Principal investigator 1 Genentech, Inc. $10,988.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649935
Principal investigator 1 Genentech, Inc. $11,166.00 11/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649946
Principal investigator 1 Eli Lilly and Company $499.84 10/27/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
A PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF OLOMORASIB IN COMBINATION WITH STANDARD OF CARE IMMUNOTHERAPY IN PARTICIPANTS WITH RESECTED OR UNRESECTABLE KRAS G12C-MUTANT, NON-SMALL CELL LUNG CANCER - SUNRAY-02 No dispute reported 06/30/2026 1187882236
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,686.50 08/20/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185550984
Principal investigator 1 Genentech, Inc. $23,950.00 07/10/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211649870
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,175.00 06/04/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185550982
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,250.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185550980